Understanding Gastroparesis Risk with Ozempic in Illinois

From General Health Information to Occupational Exposure Concerns

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. This condition, characterized by delayed stomach emptying, has been linked to GLP-1 receptor agonists like Ozempic. Building on a long history of pharmacovigilance, this page explains what gastroparesis is, how it relates to Ozempic, and what monitoring considerations exist in Illinois.

Bridging General Awareness to Specific Legal and Medical Risks

Building on the foundation of general health information, it is essential to transition to the specific medical and legal risks associated with Ozempic and gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may result in malnutrition, dehydration, and electrolyte imbalances. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology includes slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. However, this effect can become pathological in some patients, potentially contributing to the development or exacerbation of gastroparesis. The mechanistic pathway linking Ozempic to gastroparesis involves prolonged inhibition of gastric motility, which may lead to stasis, bezoar formation, and chronic symptoms consistent with gastroparesis.

Clinical Evidence and Adverse Reaction Data

Clinical trial data from the Ozempic prescribing information document a higher incidence of gastrointestinal adverse reactions among treated patients compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus included nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a clinical trial with 959 patients treated with Ozempic 1 mg or Ozempic 2 mg once weekly as add-on to metformin with or without sulfonylurea treatment for 40 weeks, no new safety signals were identified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Legal Context: Statute of Limitations in Illinois

Settlement-related considerations for affected patients in Illinois involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the timeline between exposure and documented harm is critical. Symptoms may emerge during dose escalation or after prolonged use, and diagnosis may be delayed. Patients should document the date of first Ozempic use, onset of gastrointestinal symptoms, and date of gastroparesis diagnosis to establish the discovery date. The statute of limitations may begin at diagnosis or when symptoms became severe enough to warrant medical evaluation. Legal consultation is recommended to assess individual circumstances, as failure to file within the statutory period can bar recovery. In summary, the evidence indicates a higher incidence of gastrointestinal adverse reactions with Ozempic, including nausea, vomiting, and abdominal pain, which overlap with gastroparesis symptoms. The mechanistic plausibility of Ozempic contributing to gastroparesis, combined with the absence of explicit warnings, forms the basis for potential claims. Illinois patients must be mindful of the two-year statute of limitations from the discovery of harm. Settlement considerations may include the strength of the causal link, adequacy of warnings, and individual exposure timeline.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis allegedly caused by Ozempic, the timeline between exposure and documented harm is critical. Patients should document the date of first Ozempic use, onset of gastrointestinal symptoms, and date of gastroparesis diagnosis to establish the discovery date. Legal consultation is recommended to assess individual circumstances, as failure to file within the statutory period can bar recovery.

What evidence links Ozempic to gastroparesis?

Clinical trial data from the Ozempic prescribing information document a higher incidence of gastrointestinal adverse reactions among treated patients compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathway involves prolonged inhibition of gastric motility, which may lead to stasis and chronic symptoms consistent with gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Treatment for severe Gastroparesis after Ozempic
• Ozempic Gastroparesis lawsuit settlement criteria
• Statute of limitations for Ozempic in Virginia
• Georgia Ozempic Gastroparesis injury lawyer
• Michigan Ozempic Gastroparesis injury lawyer

References

1. Ozempic Prescribing Information - DailyMed

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.